Next-Generation Antibody-Drug Conjugates for safer and more effective cancer therapies

Project Information

ADC

Grant agreement ID: 729143

DOI 10.3030/729143

Closed project

EC signature date 6 September 2016

Start date 1 May 2016

End date 30 September 2016

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

ONCOLINX UK LIMITED
United Kingdom